SPRINGWORKS THERAPEUTICS INC's ticker is SWTX and the CUSIP is 85205L107. A total of 182 filers reported holding SPRINGWORKS THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 0.26 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $388,302 | +176.4% | 10,308 | +261.2% | 0.01% | +133.3% |
| Q1 2024 | $140,474 | -17.6% | 2,854 | -38.9% | 0.00% | +50.0% |
| Q4 2023 | $170,491 | +514.0% | 4,671 | +288.9% | 0.00% | +100.0% |
| Q3 2023 | $27,767 | -66.1% | 1,201 | -61.5% | 0.00% | -66.7% |
| Q2 2023 | $81,858 | +166957.1% | 3,122 | +64.3% | 0.00% | +50.0% |
| Q1 2023 | $49 | -83.1% | 1,900 | -83.0% | 0.00% | -83.3% |
| Q4 2022 | $290 | -99.6% | 11,146 | +330.3% | 0.01% | +1100.0% |
| Q3 2022 | $74,000 | -78.6% | 2,590 | -81.6% | 0.00% | -87.5% |
| Q2 2022 | $346,000 | -0.3% | 14,083 | +128.7% | 0.01% | +166.7% |
| Q1 2022 | $347,000 | -0.6% | 6,158 | +9.3% | 0.00% | -50.0% |
| Q4 2021 | $349,000 | +47.3% | 5,633 | +50.9% | 0.01% | 0.0% |
| Q3 2021 | $237,000 | -35.6% | 3,732 | -16.3% | 0.01% | -40.0% |
| Q2 2021 | $368,000 | +503.3% | 4,458 | +437.1% | 0.01% | +900.0% |
| Q1 2021 | $61,000 | -11.6% | 830 | -12.8% | 0.00% | -50.0% |
| Q4 2020 | $69,000 | -86.6% | 952 | -91.2% | 0.00% | -66.7% |
| Q3 2020 | $516,000 | +416.0% | 10,815 | +356.3% | 0.01% | +50.0% |
| Q2 2020 | $100,000 | +354.5% | 2,370 | +133.7% | 0.00% | +100.0% |
| Q3 2019 | $22,000 | – | 1,014 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 7,281,307 | $347,100,000 | 32.35% |
| BVF INC/IL | 2,053,991 | $97,914,000 | 5.33% |
| Samsara BioCapital, LLC | 398,017 | $18,973,000 | 5.29% |
| Orbimed Advisors | 7,406,307 | $353,059,000 | 4.44% |
| Consonance Capital Management LP | 602,732 | $28,732,000 | 3.50% |
| Boxer Capital, LLC | 2,075,905 | $98,958,000 | 3.42% |
| Perceptive Advisors | 3,481,148 | $165,946,000 | 2.42% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,234,262 | $58,837,000 | 1.43% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 974,915 | $46,474,000 | 0.95% |
| HighVista Strategies LLC | 11,477 | $547,000 | 0.40% |